Related Experiment Video

Updated: Mar 4, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

935

Psoriasis and Pro-angiogenetic Factor CD93: Gene Expression and Association with Gene Polymorphism Suggests a Role in

Albert Duvetorp1, Renate Slind Olsen, Marita Skarstedt

  • 1Division of Dermatology, Ryhov Hospital, SE-55185 Jönköping, Sweden. albert.duvetorp@gmail.com.

Acta Dermato-Venereologica
|April 20, 2017
PubMed

Insights

CD93 protein is elevated in psoriasis skin, suggesting its role in the disease. Genetic variations in CD93 are linked to psoriasis, but narrowband UVB treatment doesn't affect its skin expression.

Area of Science:

  • Immunology
  • Dermatology
  • Genetics

Background:

  • Psoriasis pathogenesis involves angiogenesis and inflammation.
  • CD93 (also known as C1qRp) is implicated in these processes.

Purpose of the Study:

  • To investigate the role of CD93 in psoriasis.
  • To assess CD93 expression and its association with genetic polymorphisms in patients with psoriasis.

Main Methods:

  • Studied CD93 in serum, peripheral blood mononuclear cells, and skin of psoriasis patients and controls.
  • Analyzed CD93 gene polymorphisms (rs2749812, rs2749817).
  • Evaluated the effect of narrowband ultraviolet B (NB-UVB) treatment on CD93 skin expression.

Main Results:

  • CD93 gene expression was significantly higher in lesional and non-lesional psoriatic skin.
  • CD93 protein was detected in dermal endothelial cells of lesional skin.
  • Psoriasis showed a significant association with the CD93 gene polymorphism rs2749817.
  • NB-UVB treatment did not alter CD93 skin gene expression.

Conclusions:

  • Increased CD93 expression in psoriatic skin and its association with the rs2749817 polymorphism suggest CD93 is involved in psoriasis pathogenesis.
  • CD93 may represent a potential therapeutic target for psoriasis.

More Related Videos

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments06:34

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

630

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56